1. First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients
- Author
-
Dunphy, Mark P., Pressl, Christina, Pillarsetty, Nagavarakishore, Grkovski, Milan, Modi, Shanu, Jhaveri, Komal, Norton, Larry, Beattie, Bradley J., Zanzonico, Pat B., Zatorska, Danuta, Taldone, Tony, Ochiana, Stefan O., Uddin, Mohammad M., Burnazi, Eva M., Lyashchenko, Serge K., Hudis, Clifford A., Bromberg, Jacqueline F., Schöder, Heiko M., Fox, Josef J., Zhang, Hanwen, Chiosis, Gabriela, Lewis, Jason S., and Larson, Steven M.
- Subjects
Adult ,Male ,Middle Aged ,Article ,Iodine Radioisotopes ,Purines ,Cell Line, Tumor ,Neoplasms ,Positron Emission Tomography Computed Tomography ,Humans ,Female ,Tissue Distribution ,Benzodioxoles ,HSP90 Heat-Shock Proteins ,Aged ,Cell Proliferation - Abstract
PURPOSE: (124)I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducted a first-in-human study of microdose (124)I-PU-H71 for positron emission tomography (PET) to study in vivo biodistribution, pharmacokinetics, metabolism, and safety; and the feasibility of epichaperome-targeted tumor imaging. EXPERIMENTAL DESIGN: Adult patients with cancer (n=30) received (124)I-PU-H71 tracer (201±12 MBq
- Published
- 2020